Latest News and Press Releases

OCEANSIDE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc. (OTC Markets: TSOI) announced today filing of a patent covering novel clinical...

Company Files Patent and Generates Proof of Concept Data using NeuroStilbene for Prevention of Football Associated Brain Damage OCEANSIDE, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) --  via OTC PR...

Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA under President Donald Trump's Right to Try Law OCEANSIDE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) --...

Company to Advance NeuroStilbene Product for High-Performance AthletesSusceptible to Head Injuries OCEANSIDE, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions...

Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline OCEANSIDE, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR...

Company Expands Product Pipeline in Neurodegenerative Arena OCEANSIDE, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI)...

Company Focuses on Non-Toxic Therapies Using Immune System to Selectively Kill Cancer Cells through Immunotherapy OCEANSIDE, Calif., July 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE --...

Company Expands its Pterostilbene Based Portfolio into Brain Cancers OCEANSIDE, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC...

Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy OCEANSIDE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Via OTC PR...

Early Clinical Trial Data Supports Enhanced Biodistribution of NanoStilbene™ Compared to Standard Pterostilbene When Orally Administered OCEANSIDE, Calif., July 02, 2018 (GLOBE NEWSWIRE) --...